CCR5 and breast cancer: The recruitment and polarization of TAMs by the CCL5 axis is blocked by maraviroc (FDA-approved CCR5 inhibitor), which inhibits BC growth and metastasis and improves the overall survival rate for breast malignant phyllodes tumor [167].